Key Developments: MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

17 Oct 2014
Price Change (% chg)

$-0.50 (-10.73%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

MediciNova, Inc announces FDA granted orphan drug designation to MN-001 for Idiopathic Pulmonary Fibrosis
Wednesday, 22 Oct 2014 07:00pm EDT 

MediciNova, Inc:Says that the U.S. Food and Drug Administration has granted orphan-drug designation to MN-001 (tipelukast) for treatment of idiopathic pulmonary fibrosis.Says Orphan-drug designation will provide MediciNova with seven years of marketing exclusivity for MN-001 (tipelukast) for the treatment of IPF if it is approved for this indication.  Full Article

MediciNova, Inc to initiate clinical trial of MN-166 (ibudilast) in ALS
Monday, 25 Aug 2014 07:15pm EDT 

MediciNova, Inc:Announces FDA approval to initiate a clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS).Says the principal investigator of the study is Benjamin Rix Brooks, MD, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute in Charlotte, NC.Says the study is funded by MediciNova with the support of Carolinas HealthCare System.  Full Article

MediciNova, Inc announces positive interim results of Phase 2a Study of MN-166 in Opioid Dependence
Monday, 18 Aug 2014 07:00pm EDT 

MediciNova, Inc:Announces positive interim results of a Phase 2a clinical trial of MN-166 (ibudilast) in opioid dependence.The study is being conducted at Columbia University and the New York State Psychiatric Institute and led by Sandra Comer, Professor of Neurobiology.The interim analysis was performed after the first seven patients had completed the study, which required a 6-week stay on the inpatient unit.Says this data is complementary to the data from the company's previous study in heroin abusers, in which ibudilast demonstrated a reduction in withdrawal symptoms.Says the data also confirms the positive effects of ibudilast on analgesia which the company have seen in a previous study.  Full Article

Medicinova Inc receives notice of allowance for new patent covering MN-001 AND MN-002 for the treatment of nonalcoholic fatty liver disease
Monday, 11 Aug 2014 07:00pm EDT 

Medicinova Inc:Says that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of nonalcoholic fatty liver disease (NAFLD).Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than Dec. 2032.Says the allowed claims cover a method of treating nonalcoholic fatty liver disease (NAFLD) and a method of reducing liver inflammation in nonalcoholic fatty liver disease (NAFLD) using MN-001 or MN-002.Says the allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.  Full Article

Medicinova announces positive results of MN-001 in Advanced NASH Mouse Model
Tuesday, 5 Aug 2014 07:30am EDT 

Medicinova Inc:Says positive results from a second preclinical study that examined the potential clinical efficacy of MN-001 for the treatment of advanced NASH (nonalcoholic steatohepatitis with fibrosis).Study used mice in more advanced stages of NASH as compared to the first study of MN-001 in a NASH mouse model.  Full Article

MediciNova Inc announces positive results in study of MN-001 in mouse model of pulmonary fibrosis
Wednesday, 11 Jun 2014 07:00pm EDT 

MediciNova Inc:Says positive results from a study that examined potential clinical efficacy of MN-001 (tipelukast) for treatment of pulmonary fibrosis.MN-001, which was administered orally once daily (30, 100 and 300 mg/kg) for 2 weeks, was evaluated in a mouse model of bleomycin-induced pulmonary fibrosis (PF).As measured by CT evaluation of lung density, degree of pulmonary fibrosis using the Ashcroft score based on histopathological staining, and hydroxyproline content, which is an indicator of fibrosis or storage of collagen in tissue.MN-001 significantly decreased (p<0.05) the Ashcroft score compared to Vehicle group after two weeks of treatment and MN-001 reduced lung density when compared to Vehicle-treated group.Moreover, lung hydroxyproline content was significantly reduced compared to Vehicle group (p<0.01).Says these results show that treatment with MN-001 has significant anti-fibrogenic effects in bleomycin-induced pulmonary fibrosis in mice.  Full Article

Medicinova Inc announces appointment of Chief Financial Officer
Tuesday, 8 Apr 2014 07:00pm EDT 

Medicinova Inc:Announced the appointment of Esther van den Boom as Chief Financial Officer.  Full Article

Medicinova Inc announces positive results in NASH Mouse Model with MN-001 and prepares to initiate phase 2 trial in the U.S.
Tuesday, 14 Jan 2014 08:00am EST 

Medicinova Inc:Says it has announced positive results from a study that examined the potential clinical efficacy of MN-001 for the treatment of NASH (nonalcoholic steatohepatitis).Says MN-001 administered orally once daily (10, 30, and 100 mg/kg) for 3 weeks, was evaluated in the STAM mouse model of nonalcoholic steatohepatitis, as measured by liver biochemistry and histopathology, NAFLD activity score (NAS), and percent of fibrosis and gene expression.Says MN-001, in a dose-dependent manner, significantly reduced fibrosis area compared with vehicle (p <0.01) as demonstrated by a reduction in liver hydroxyproline content, supporting MN-001's anti-fibrotic properties.  Full Article

Medicinova Inc Announces Board Change-Form 8-K
Wednesday, 13 Nov 2013 06:02am EST 

Medicinova Inc reported in its Form 8-K that on November 8, 2013, the Company gave notice of termination of the Confidential Consulting Agreement dated September 1, 2011 by and between the Company and FLG Partners, LLC, pursuant to which Michael J. Gennaro was appointed to serve as the Company’s Chief Financial Officer (CFO). Concurrently with the notice of termination, Mr. Gennaro no longer serves as the Company’s principal financial officer and principal accounting officer. Effective November 11, 2013, the Company retained the accounting services firm of Mead van den Boom & Associates to replace Mr. Gennaro and FLG Partners, LLC in its financial reporting oversight role. During a transition period, Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer (CEO) of the Company, will also serve as the Company’s Acting Chief Financial Officer (CFO) and its principal financial officer and principal accounting officer.  Full Article

Medicinova Inc Receives New Patent Covering MN-221 In Irritable Bowel Syndrome
Monday, 11 Nov 2013 06:00pm EST 

Medicinova Inc announced that a new U.S. patent has been granted which covers MN-221 in the treatment of irritable bowel syndrome. The new patent (U.S. Patent No. 8,518,995) will expire no earlier than April 2031. The claims cover a method for treatment of irritable bowel syndrome using certain compounds including MN-221. The claims cover various routes of administration including oral, injectable and transdermal.  Full Article

Search Stocks